CD274 and non-small cell lung carcinoma: Clinical trials also suggested that patients with high tissue-based TMB (tTMB) can obtain better efficacy from PD-1/PD-L1 inhibitor therapy for nonsmall cell lung cancer (NSCLC), melanoma and gastric cancer [11–13].